FCRL5 and Miyoshi myopathy: Chromosome 1q amplification is a frequent genetic abnormality observed in MM patients and serves as a biomarker of aggressive disease.44 Recent studies have shown that bortezomib and immunomodulatory agents do not improve adverse effects or prognosis in patients with MM harboring 1q amplification.45 Li et al.20 demonstrated that FCRL5 overexpression is associated with gain of 1q21 in high-risk MM patients.